Beam Therapeutics vs Verve Therapeutics
Beam Therapeutics and Verve Therapeutics were the two leading base editing companies, but the landscape shifted dramatically in 2025. Eli Lilly acquired Verve Therapeutics for up to $1.3B (completed July 2025), making Verve's cardiovascular base editing programs part of Lilly's portfolio. Meanwhile, Beam achieved the historic first clinical correction of a disease-causing mutation (BEAM-302, March 2025) and landed $500M+ in pharma deals with Pfizer ($300M) and Lilly ($200M). This comparison reflects the divergent paths of an independent biotech pioneer vs. a big pharma-absorbed program.
Last updated: March 29, 2026
Beam Therapeutics (BEAM)
Founded by base editing inventor David Liu, Beam holds the broadest base editing patent portfolio and has achieved landmark clinical milestones. The company is targeting its first BLA submission by year-end 2026.
Verve Therapeutics (Eli Lilly subsidiary)
Formerly a public company focused on using base editing to permanently lower cholesterol, Verve was acquired by Eli Lilly for up to $1.3B in July 2025. Its programs now operate within Lilly's cardiovascular division with big pharma resources.
Key Specifications
| Feature | Beam Therapeutics (BEAM) | Verve Therapeutics (Eli Lilly subsidiary) |
|---|---|---|
| Ticker | BEAM (NASDAQ) | — |
| Market cap (Mar 2026) | ~$2.8B | — |
| Stock price | ~$26 (52wk: $14-$36) | — |
| 2025 revenue | $139.7M (+120% YoY, collaboration) | — |
| Lead program | BEAM-101 (risto-cel) — SCD, BLA target YE 2026 | VERVE-102 (next-gen PCSK9 base editor) — Phase 1b |
| Key milestone | First clinical genetic correction (BEAM-302, Mar 2025) | — |
| Major deals | Pfizer $300M + Lilly $200M (2025) | — |
| Technology | Adenine & cytosine base editing | Adenine base editing (in vivo, LNP liver-directed) |
| Pipeline | BEAM-101 (SCD), BEAM-302 (AATD), BEAM-301 (GSD1a), BEAM-103 (anti-CD117) | — |
| Founded | 2017 (Cambridge, MA) | 2018 (Cambridge, MA) by Sekar Kathiresan, M.D. |
| Key advantage | Broadest base editing IP + inventor-founder (David Liu) | — |
| Status | — | Wholly-owned Eli Lilly subsidiary (acquired July 2025) |
| Acquisition price | — | $10.50/share + up to $3.00/share CVR = $13.50 total (~$1.3B) |
| Premium paid | — | 113% over 30-day VWAP |
| Deprioritized | — | VERVE-101 (original PCSK9 editor) — safety concerns |
| Second program | — | VERVE-201 (ANGPTL3) — preclinical |
| Key result | — | VERVE-102: 53-69% LDL-C reduction, no treatment-related SAEs |
| Market | — | Cardiovascular disease — $100B+ addressable |
| Acquirer rationale | — | Lilly sees one-time cholesterol cure as transformative for CVD franchise |
Beam Therapeutics (BEAM)
Advantages
- Historic milestone: first-ever clinical genetic correction of a disease-causing mutation (BEAM-302, AATD, March 2025)
- BEAM-101 (risto-cel) for SCD: 30 patients dosed, FDA RMAT designation (Aug 2025), BLA targeted year-end 2026
- BEAM-302 for AATD: FDA aligned on accelerated approval via biomarker endpoint — first correction-based gene editing therapy
- Massive pharma validation: Pfizer deal $300M upfront + $1.05B milestones; Lilly deal $200M + $350M milestones
- BEAM-301 for GSD1a: Phase 1/2 ongoing, Cohort 2 enrollment initiated
- Revenue: $139.7M in 2025 (+120% YoY) from collaborations
- Both ex vivo and in vivo delivery platforms — diversified approach
Limitations
- No approved products yet — all revenue from partnerships, not product sales
- Complex ex vivo manufacturing for lead program BEAM-101 (similar to Casgevy challenges)
- Stock volatile: ~$26 (52-week range: $14-$36) — typical clinical-stage biotech risk
- Portfolio prioritization in 2025 — some earlier programs deprioritized
- Competing with Casgevy (already approved) for sickle cell disease market
- In vivo programs earlier-stage — liver-directed base editing faces Verve's safety learnings
Verve Therapeutics (Eli Lilly subsidiary)
Advantages
- Massive addressable market: cardiovascular disease is #1 killer globally, $100B+ market
- VERVE-102 (next-gen): dose-dependent LDL-C reduction of 53-69% from single IV dose — no treatment-related SAEs
- Eli Lilly backing: $1.3B acquisition provides unlimited resources vs. biotech cash constraints
- Simple value proposition: one injection to permanently lower cholesterol — no daily pills
- In vivo LNP delivery — no cell extraction, simple IV infusion
- CVR structure: $3/share bonus if VERVE-102 reaches US Phase 3 (10-year window)
Limitations
- No longer independent: absorbed into Lilly, investor exposure only via LLY stock
- VERVE-101 deprioritized after safety signals: grade 3 ALT, thrombocytopenia, potentially related MI, patient death
- Patient death in Heart-1 trial (fatal cardiac arrest ~5 weeks post-infusion) — determined related to underlying ASCVD, not treatment, but cast shadow
- Competing with cheap, effective statins and PCSK9 inhibitors (inclisiran) — high bar for market adoption
- In vivo liver base editing is irreversible — safety bar for chronic disease in otherwise healthy patients is extremely high
- Years away from approval — CVR trigger requires Phase 3 start within 10 years
The Verdict
The Beam vs Verve comparison has fundamentally changed. Beam is the independent base editing platform company: diversified pipeline, historic first clinical genetic correction, $500M+ in pharma deals, and a BLA-track program (BEAM-101). Verve's acquisition by Lilly for $1.3B validated the cardiovascular base editing thesis but removed it as a standalone investment. For investors, Beam ($2.8B market cap) is the pure-play base editing bet — if BEAM-101 gets approved, it could become the second CRISPR-era therapy after Casgevy. Verve's programs now have Lilly's resources behind them, but the VERVE-101 safety setback and the high bar for treating chronic disease in otherwise healthy patients with irreversible gene editing mean the path to market is longer and riskier than initially hoped.